Abstract
Background Abilar® is a wound salve containing 10 % medical-grade Norway spruce (Picea abies) resin, known for its antimicrobial and wound-healing properties. However, isolated reports of allergic contact dermatitis have raised concerns regarding its cutaneous safety profile. Given the increasing use of Picea abies resin-based products, it is important to evaluate any potential for skin irritation and sensitization.
Objectives To evaluate the irritation and sensitization potential of medical-grade Picea abies resin salve using a modified Draize Human Repeat Insult Patch Test (HRIPT) in a healthy adult cohort, thereby providing toxicological insights relevant to both clinical applications and consumer safety.
Methods A single-blind study (ClinicalTrial.gov, Identifier: NCT06810856) was conducted with 215 healthy volunteers (207 completed the study). Medical-grade Picea abies resin salve was applied through cutaneous patches in an induction phase and a challenge phase. Skin reactions were evaluated using modified Draize scoring system, with reactions to both the test material and adhesive being recorded separately.
Results During the induction phase, only 7 of 207 subjects (3.38%) of participants exhibited mild erythema (Grade 1) attributed to the resin salve. Notably, no participant experienced moderate to severe reactions (Grades 2–5). In the subsequent challenge phase, no reactions were observed, and subjects with prior Grade 1 responses reverted to a non-reactive status. These findings indicate that, under the test conditions and repeated exposure regimen, the medical-grade Picea abies resin salve demonstrates a low potential for inducing cutaneous irritation or sensitization.
Conclusions The HRIPT findings demonstrate that medical-grade Picea abies resin salve has a low irritation and sensitization potential under the conditions tested. Although rare cases of allergic contact dermatitis have been documented in literature in predisposed individuals, the data of this study suggests that the overall risk in the general population is low. These findings are also supported by clinical studies and extensive post-market surveillance of Abilar® in wound care for both acute and chronic wounds.
Competing Interest Statement
Dr. Evgen Multia and Kamilla Yamileva are employees of Repolar Pharmaceuticals Ltd., the manufacturer of Abilar Resin Salve.
Clinical Trial
NCT06810856
Funding Statement
This study was funded by Repolar Pharmaceuticals Ltd.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of East Anglia gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† Kamilla Yamileva and Evgen Multia should be considered joint first authors.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
